Daily non-political popular news in brief.
Cetuximab with radiotherapy does not increase side effects for head and neck cancer patients
01-18-2007 · EurekAlert!The addition of Cetuximab (brand name Erbitux) to radiation therapy treatments does not increase the rate or duration of some side effects in the treatment of advanced head and neck cancers, according to a study presented at the plenary session today at the Multidisciplinary Head and Neck Cancer Symposium, co-sponsored by the American Society for Therapeutic Radiology and Oncology, the American Society for Clinical Oncology and the American Head and Neck Society.
Read more »
Keywords: cetuximab, radiotherapy, side, effects, head, neck, cancer, patients, effect, patient
« Previous | Next »
Similar news on "Cetuximab with radiotherapy does not increase side effects for head and neck cancer patients":
- Sunshine pill for prostate cancer in 2009
01-16-2007 · EurekAlert!
A drug based on vitamin D and is given to patients in the advanced stages of prostate cancer along with chemotherapy drugs could be availiable by 2009. Vitamin D from sunlight improves the prognosis of certain cancers, but taking natural levels of the vitamin has no effect. Novacea, the company that makes Asentar, produced a novel formulation that reproduces the healing effect without the dangerous side-effects of a vitamin D overdose.
Similar news · Read more »
- Decrease in the use of radiotherapy procedures for the treatment of cancer in hospitals
10-09-2007 · EurekAlert!
The study is based on data of patients, treated in any of the 10 Andalusian public hospitals for one year, who were submitted to radiotherapy procedures for the treatment of tumours in the breast, lung, head and neck, cervix and endometrium.
Similar news · Read more »
- Cetuximab may prolong survival for head and neck cancer patients
01-18-2007 · EurekAlert!
Preliminary findings show adding the chemotherapy drug cetuximab (brand name Erbitux) to radiation therapy and chemotherapy may help some patients with head and neck cancer live longer, according to a study presented at the plenary session of the Multidisciplinary Head and Neck Cancer Symposium, co-sponsored by the American Society for Therapeutic Radiology and Oncology, the American Society for Clinical Oncology and the American Head and Neck Society.
Similar news · Read more »
- A new radiation therapy treatment developed for head and neck cancer patients
08-17-2007 · EurekAlert!
Most head and neck cancers that recur locally after prior full-dose conventional radiation therapy respond to Boron Neutron Capture Therapy suggests the recent Finnish study. Dr. Heikki Joensuu, professor of radiotherapy and oncology at the University of Helsinki, considers the results clinically significant and very interesting: They open a new field for BNCT, since thus far BNCT has been evaluated only in the treatment of some brain tumours.
Similar news · Read more »
- Gene patenting -- steep cost for health care and patients
05-07-2007 · EurekAlert!
The drug trastuzumab (Herceptin) is used to treat HER2-positive breast cancer (a type of breast cancer that overexpresses the HER2 gene and accounts for about 25 percent of all breast cancers). Trastuzumab therapy improves the chances of survival; however, it has deleterious side effects and is expensive. Thus, it is important to accurately determine the patient's HER2 status.
Similar news · Read more »
- Intensity-modulated radiation therapy reduces side effects for cervical cancer
11-07-2006 · EurekAlert!
Administering extended-field intensity-modulated radiation therapy (IMRT) for cervical cancer resulted in significantly reduced side effects and outcomes comparable to standard radiotherapy. In the University of Pittsburgh study, 36 patients with cervical cancer were treated with extended-field IMRT and the chemotherapy agent cisplatin to determine the efficacy of treatment and treatment-related side effects.
Similar news · Read more »
- Intravenous chemoradiation effective for inoperable head, neck cancer; easier for patients, doctors
11-06-2006 · EurekAlert!
Chemoradiation (radiation and chemotherapy given at the same time) given through a needle or tube inserted into a vein (intravenous) is as effective as treatment given directly to the tumor through a tube inserted into an artery (intra-arterial) for patients with inoperable head and neck cancer, according to a randomized study presented at the plenary session November 6, 2006, at the American Society for Therapeutic Radiology and Oncology's 48th Annual Meeting in Philadelphia.
Similar news · Read more »
- Gene variations point to why lung cancer drugs work better in Japanese vs. US patients
06-02-2007 · EurekAlert!
Recent clinical trials revealed that Japanese lung cancer patients survived longer and had a higher rate of side effects than US patients taking the same two drugs, paclitaxel and carboplatin. Now a new study by the Southwest Oncology Group uncovers genetic differences that may explain why. The results, embargoed for release 8:30 a.m. ET Saturday, June 2, are being highlighted at the American Society of Clinical Oncology annual meeting.
Similar news · Read more »
- Cancer researchers seek safe reduction of radiotherapy
10-02-2007 · EurekAlert!
University of Manchester scientists will discuss their research aimed at reducing the side effects of radiotherapy without decreasing its effectiveness at the National Cancer Research Institute conference in Birmingham today Tuesday, Oct. 2, 2007.
Similar news · Read more »
- Saving salivary glands from the collateral damage of radiation therapy
10-27-2006 · EurekAlert!
Researchers have shown that targeted overexpression of heat shock protein 25 prevents radiation-induced damage to salivary glands, a common consequence of treatment for head and neck cancer. The related report by Lee et al., "Radioprotective effect of HSP25 on submandibular glands of rats," appears in the November issue of the American Journal of Pathology.
Similar news · Read more »
